Teva Pharmaceuticals Initiates Voluntary Nationwide Recall of Seven Lots of Amikacin Sulfate Injection USP 500 mg/2 mL (250 mg/mL) and 1 Gram/4 mL (250 mg/mL) Vials Due to Potential of Glass Particulate Matter

Food & Drug Recalls

Teva Pharmaceuticals of North Wales, PA, today announced a voluntary recall of seven lots of Amikacin Sulfate Injection USP, 500 mg/2mL (250 mg/mL) and 1 gram/4mL (250 mg/mL) vials due to the potential for the presence of glass particulate matter.